trending Market Intelligence /marketintelligence/en/news-insights/trending/2nno7_Fjklbki_kZeCmAhA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Oyster Point's nasal spray improves tear production in dry eye patients in study

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Oyster Point's nasal spray improves tear production in dry eye patients in study

Oyster Point Pharma Inc. said its nasal spray OC-O1 helped patients with dry eye disease achieve better tear production compared to vehicle, thereby meeting the main goal of mid-stage study.

The Princeton, N.J.-based biopharmaceutical company evaluated two doses of OC-O1 against a vehicle — a dermatologic drug product — in a phase 2 trial, dubbed Mystic to treat patients with dry eye disease, a condition where the tears are not able to provide adequate lubrication for the eyes.

Oyster Point, which went public in the latter half of 2019, said in a Jan. 12 press release that OC-O1 works by stimulating natural tear production in the eye.

The company said that following 84 days of treatment, both doses, the 1.2 milligram/milliliter dose and 0.6 milligram/milliliter dosage, of OC-O1 showed a statistically significant improvement on the Schirmer's test — used for determining whether the eye produces enough tears to keep it moist — compared to the vehicle.

OC-01 was well-tolerated for both the two doses and the number of people reporting any treatment-emergent adverse event was the same in the two groups of patients.

Oyster Point added that it expects to discuss data from a phase 3 trial, dubbed Onset-2, in dry eye disease by the middle of the year.